CVS Caremark (NYSE: CVS)‘s stock had its “neutral” rating reaffirmed by Zacks in a report released on Thursday, StocKRatingsNetwork.com reports. They currently have a $62.00 target price on the stock.

Zacks‘ analyst wrote, “CVS posted a solid first-quarter 2013 with 28.1% year over year rise in adjusted EPS to $0.83, beating the Zacks Consensus Estimate of $0.79. Although net revenue declined 0.1% to $30.8 billion with slowdown in segmental growth, it remained ahead of the Zacks Consensus Estimate of $30.3 billion. The generic wave in the pharmaceutical industry continues to work in CVS’ favor, as seen in the consistent margin expansion of the company. CVS narrowed its guidance for 2013 adjusted EPS. The guidance for the second quarter is also encouraging. On the tepid side, the sluggish segment growth failed to boost confidence. Despite several favorable events, the decline in same-store and pharmacy store sales are notable downsides. Competitive landscape is also tough. Thus, we reiterate our Neutral recommendation on the stock.”

Shares of CVS Caremark (NYSE: CVS) traded up 0.29% during mid-day trading on Thursday, hitting $58.92. CVS Caremark has a 52 week low of $43.30 and a 52 week high of $58.50. The stock’s 50-day moving average is currently $55.12. The company has a market cap of $72.542 billion and a P/E ratio of 19.42.

CVS Caremark (NYSE: CVS) last announced its earnings results on Wednesday, May 1st. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $30.76 billion for the quarter, compared to the consensus estimate of $30.36 billion. During the same quarter last year, the company posted $0.65 earnings per share. CVS Caremark’s revenue was down .1% compared to the same quarter last year. CVS Caremark has set its Q2 guidance at $0.94-0.97 EPS and its FY13 guidance at $3.89-4.00 EPS. On average, analysts predict that CVS Caremark will post $3.97 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Cantor Fitzgerald raised their price target on shares of CVS Caremark from $57.00 to $65.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Barclays Capital raised their price target on shares of CVS Caremark from $57.00 to $67.00 in a research note to investors on Thursday. They now have an “overweight” rating on the stock. Finally, analysts at Goldman Sachs reiterated a “neutral” rating on shares of CVS Caremark in a research note to investors on Thursday. They now have a $61.00 price target on the stock.

Two analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. CVS Caremark has a consensus rating of “Buy” and a consensus price target of $59.03.

CVS Caremark Corporation (NYSE: CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.